28 Sep 2018
On Track - H1 recovery - solid H2 outlook
AVO reported its H1/2018 results today. The company has managed to turn the corner with a solid financial position and its completion of c.£40m financing round and ending the share overhang from debt equity facilities. The beam testing is progressing and company's outlook confirmed first patient treatment with LIGHT by mid 2020. The new commercial distribution agreement in Asia with Liquid Harmony put the company in a robust commercial position. LIGHT has a greater potential than PT cyclotrons t ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
On Track - H1 recovery - solid H2 outlook
Advanced Oncotherapy Plc (AVO:LON) | 1.9 0 0.0% | Mkt Cap: 10.4m
- Published:
28 Sep 2018 -
Author:
Martin Brunninger -
Pages:
5
AVO reported its H1/2018 results today. The company has managed to turn the corner with a solid financial position and its completion of c.£40m financing round and ending the share overhang from debt equity facilities. The beam testing is progressing and company's outlook confirmed first patient treatment with LIGHT by mid 2020. The new commercial distribution agreement in Asia with Liquid Harmony put the company in a robust commercial position. LIGHT has a greater potential than PT cyclotrons t ....